User login
Key clinical point: Patients with metastatic colorectal cancer (mCRC) show a clear-cut attrition across subsequent lines of therapy, with most patients with RAS/BRAF wild-type mCRC opting for anti-epidermal growth factor receptor (EGFR)-containing regimens as the treatment of choice after the second progressive disease (PD).
Major finding: The number of patients receiving subsequent systemic treatment decreased with each progressive line of therapy (53%, 27%, and 11% of patients received treatment after the second, third, and fourth PD, respectively). After the second PD, anti-EGFR-containing regimens were preferred by most (67%) patients with RAS/BRAF wild-type mCRC.
Study details: This pooled analysis study included 1187 patients with mCRC from two phase 3 trials, TRIBE and TRIBE2, who received fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) + bevacizumab or doublets (fluorouracil + oxaliplatin [FOLFOX] or fluorouracil + irinotecan [FOLFIRI]) + bevacizumab as the first-line therapy.
Disclosures: The study was supported by the GONO and ARCO Foundations. Some authors declared serving as consultants, advisors, or speakers for or receiving honoraria or research funding from various organizations.
Source: Rossini D et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64-72 (May 17). Doi: 10.1016/j.ejca.2022.04.019
Key clinical point: Patients with metastatic colorectal cancer (mCRC) show a clear-cut attrition across subsequent lines of therapy, with most patients with RAS/BRAF wild-type mCRC opting for anti-epidermal growth factor receptor (EGFR)-containing regimens as the treatment of choice after the second progressive disease (PD).
Major finding: The number of patients receiving subsequent systemic treatment decreased with each progressive line of therapy (53%, 27%, and 11% of patients received treatment after the second, third, and fourth PD, respectively). After the second PD, anti-EGFR-containing regimens were preferred by most (67%) patients with RAS/BRAF wild-type mCRC.
Study details: This pooled analysis study included 1187 patients with mCRC from two phase 3 trials, TRIBE and TRIBE2, who received fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) + bevacizumab or doublets (fluorouracil + oxaliplatin [FOLFOX] or fluorouracil + irinotecan [FOLFIRI]) + bevacizumab as the first-line therapy.
Disclosures: The study was supported by the GONO and ARCO Foundations. Some authors declared serving as consultants, advisors, or speakers for or receiving honoraria or research funding from various organizations.
Source: Rossini D et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64-72 (May 17). Doi: 10.1016/j.ejca.2022.04.019
Key clinical point: Patients with metastatic colorectal cancer (mCRC) show a clear-cut attrition across subsequent lines of therapy, with most patients with RAS/BRAF wild-type mCRC opting for anti-epidermal growth factor receptor (EGFR)-containing regimens as the treatment of choice after the second progressive disease (PD).
Major finding: The number of patients receiving subsequent systemic treatment decreased with each progressive line of therapy (53%, 27%, and 11% of patients received treatment after the second, third, and fourth PD, respectively). After the second PD, anti-EGFR-containing regimens were preferred by most (67%) patients with RAS/BRAF wild-type mCRC.
Study details: This pooled analysis study included 1187 patients with mCRC from two phase 3 trials, TRIBE and TRIBE2, who received fluorouracil, irinotecan, and oxaliplatin (FOLFOXIRI) + bevacizumab or doublets (fluorouracil + oxaliplatin [FOLFOX] or fluorouracil + irinotecan [FOLFIRI]) + bevacizumab as the first-line therapy.
Disclosures: The study was supported by the GONO and ARCO Foundations. Some authors declared serving as consultants, advisors, or speakers for or receiving honoraria or research funding from various organizations.
Source: Rossini D et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022;170:64-72 (May 17). Doi: 10.1016/j.ejca.2022.04.019